Balance Sheet Components - Assets and Liabilities Held For Sale (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue of biosimilars portfolio		$ 185.3	$ 521.3
Liabilities held for sale		335.3	335.3	$ 0.0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Biocon Biologics | Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		159.5	159.5
Inventories		163.2	163.2
Prepaid expenses and other current assets		27.0	27.0
Intangible assets, net		59.8	59.8
Goodwill		911.8	911.8
Other assets		105.1	105.1
Accounts payable		131.2	131.2
Accounts payable		202.1	202.1
Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent		$ 2.0	$ 2.0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Scenario, Forecast | Biocon Biologics | Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront payment subject to certain adjustments	$ 2,000.0
Percent ownership after transaction	12.90%
Additional cash payments to be received	$ 335.0
Term of transition services agreement	2 years